Haematopoietic stem cell mobilisation followed by high‐dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18990 ↗Kurz gefasst
Leserbrief in der Zeitschrift British Journal of Haematology, 2023. Verfasst von S Asher und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, University College Hospital London NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation, Anemia, Sickle Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Themen: Mobilisation, Onkologische Pflege
Abstract (Originalsprache)
Sickle cell disorder (SCD) is the commonest inherited single gene disorder in England with more than 14 000 individuals affected. It is seen mostly in people of African ancestry and as the life expectancy of those with SCD increases so will their lifetime risk of malignancy.1,2 There is an increased prevalence of multiple myeloma (MM) in people of African ancestry, and there are disparities in both treatments and survival outcomes compared with those of European ancestry.3 SCD is a multisystem disease and there is a progression of organ damage with age. Given the age incidence of MM, by the time those with SCD develop the disorder, there will frequently be significant organ dysfunction. As such, the myeloma and that of the underlying SCD must be carefully managed with due consideration to both disorders to ensure the best outcomes for patients.4,5 Autologous stem cell transplant (ASCT) for transplanteligible MM patients has become the standard of care (SoC).6 However, limited guidance exists on mitigating complications and optimising outcomes for these patients receiving ASCT. We report on our experiences with haematopoietic progenitor cell (HPC) mobilisation in three patients with MM and SCD, two of whom proceeded to highdose therapy (HDT). HDT was deferred for Patient 2 due to the risk of infection during the peak of the COVID19 pandemic. HDT may be required at a later date. The use of granulocytecolony stimulating factor (GCSF) is an approved and wellpractised strategy for HPC mobilisation.6 However in patients with SCD, GCSF has been associated with an increased risk of severe and even fatal VOC.7 Plerixafor is effective in HPC mobilisation for SCD.8– 10 Plerixafor is a CXCR4 antagonist which directly inhibits the binding of stromacellderived factor1a to its CXC chemokine receptor on HPCs.10 Plerixafor is safe and welltolerated in patients with SCD who have received prior red cell exchange (RCE).9 However these reports are predominantly in the context of gene therapy. For ASCT, the minimum threshold for CD34+ cell collection is currently defined as 2.0 × 106 cells/kg6 or if the CFUGM is >20 × 104 cells/kg (as practised in our centre). Successful HPC mobilisation was achieved in three patients with SCD and MM using plerixafor alone (Table 1). However, HPC yields were modest, only allowing enough cells for a single ASCT. This may limit optimal treatment for patients with highrisk diseases requiring tandem transplants. Standard dosing of plerixafor was administered (0.24 mg/kg, capped at 20 mg if weight ≤83 kg). The timing of plerixafor administration is different to that used for GCSF HPC mobilisation. Given CD34+ cell counts decline after 6 h with plerixafor,10 we suggest administering plerixafor 2– 4 h prior to apheresis and ensuring peripheral blood CD34+ dose is ≥10/μL, prior to mobilisation. Two to three daily doses are likely required to ensure adequate CD34+ yields.11 In contrast, most patients collect HPCs in 1 day with GCSF alone.12 Limited data exist for sicklerelated complications during HDT with available reports predominantly for allogeneic transplants. All ASCT planning should follow a multidisciplinary approach and include the patient's primary red cell, myeloma and transplant teams to optimise patient safety during ASCT. Maintaining HbS ≤30% is the gold standard in primary and secondary prevention as well as treatment of complications in SCD.2 To limit sicklerelated complications during ASCT we suggest considering a RCE reducing haemoglobin S (HbS) to ≤30%.8,9,13 We recommend RCE at least 7 days before HDT and to maintain the HbS ≤30%. If the patient was already established on regular RCE this should be timed to have their last preASCT, such that the HbS is
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Haematology, University College Hospital London NHS Foundation Trust, London, UK.
- Department of Haematology, Guys and St Thomas' NHS Foundation Trust, London, UK.
ORCID-Profile: S Asher, G Nesr, R Kesse Adu, M Streetly, S Trompeter, K Xu, A McMillan, J Sive
Zitieren
APA
Asher, S., Shah, R., Ings, S., Horder, J., Newrick, F., Nesr, G., Kesse Adu, R., Streetly, M., Trompeter, S., Lee, L., Wisniowski, B., Mahmood, S., Xu, K., Papanikalaou, X., McMillan, A., Popat, R., Yong, K., Sive, J., Kyriakou, C., & Rabin, N. (2023). Haematopoietic stem cell mobilisation followed by high‐dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma. British Journal of Haematology. https://doi.org/10.1111/bjh.18990
Vancouver
Asher S, Shah R, Ings S, Horder J, Newrick F, Nesr G, et al. Haematopoietic stem cell mobilisation followed by high‐dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma. British Journal of Haematology. 2023. doi:10.1111/bjh.18990
BibTeX
@article{Asher2023,
author = {Asher, S and Shah, R and Ings, S and Horder, J and Newrick, F and Nesr, G and Kesse Adu, R and Streetly, M and Trompeter, S and Lee, L and Wisniowski, B and Mahmood, S and Xu, K and Papanikalaou, X and McMillan, A and Popat, R and Yong, K and Sive, J and Kyriakou, C and Rabin, N},
title = {Haematopoietic stem cell mobilisation followed by high‐dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18990}
}
EUVIMED